<DOC>
	<DOCNO>NCT02745119</DOCNO>
	<brief_summary>This multicenter open-label extension study design evaluate safety tolerability lampalizumab intravitreal injection participant GA secondary age-related macular degeneration ( AMD ) complete 96 week treatment Studies GX29176 ( NCT02247479 ) GX29185 ( NCT02247531 ) . The extension enroll participant parent study receive investigational lampalizumab , well lampalizumab-naive participant expose sham comparator . All participant receive open-label lampalizumab present study .</brief_summary>
	<brief_title>Long-Term Safety Lampalizumab Intravitreal ( ITV ) Injections Participants With Geographic Atrophy ( GA ) Secondary Age-Related Macular Degeneration ( OMASPECT )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Previous enrollment Studies GX29176 ( NCT02247479 ) GX29185 ( NCT02247531 ) completion treatment Week 96 visit Agreement remain abstinent use reliable form contraception among men among woman childbearing potential Concurrent ocular condition contraindicate use lampalizumab might affect interpretation study result might increase risk treatment complication Concurrent disease , metabolic dysfunction , physical laboratory find contraindicates use lampalizumab might affect interpretation study result might increase risk treatment complication Increased risk infection Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>